Paper Details

  1. Home
  2. Paper Details

A critical appraisal of the selegiline transdermal system for major depressive disorder.

Author: BiedAdam M, KimJungjin, SchwartzThomas L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The selegiline transdermal system (STS) is the first antidepressant transdermal medication approved by the US FDA for the treatment of major depressive disorder. STS allows for steady release of selegiline over 24 h with minimal fluctuation in drug serum levels, reducing the risk of tyramine hypertensive crises. Patient adherence could be improved due to ease of use and once-daily dosing. STS appears to be an effective agent for major depressive disorder.
Paper Details　
Original Abstract of the Article :
The selegiline transdermal system (STS) is the first antidepressant transdermal medication approved by the US FDA for the treatment of major depressive disorder. Its unique antidepressant delivery system allows for steady release of selegiline over 24 h with minimal fluctuation in drug serum levels....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/17512433.2016.1093416

データ提供：米国国立医学図書館（NLM）

A Transdermal Revolution: Selegiline for Depression

This research delves into the exciting world of transdermal medication delivery, exploring the use of a selegiline transdermal system (STS) for treating major depressive disorder. Imagine a camel carrying a special pouch that gradually releases a healing substance, providing a steady and consistent benefit. The study highlights the unique features of STS, allowing for continuous release of selegiline with minimal fluctuations in drug levels, minimizing the risk of tyramine hypertensive crises, and offering a convenient once-daily dosing regimen. The authors review the pharmacologic properties and clinical data, exploring the efficacy and safety of STS in managing major depressive disorder.

Steady and Effective: Selegiline Transdermal System

The research found that STS effectively treats major depressive disorder, with doses between 6 and 12 mg over 24 hours demonstrating significant benefits. Furthermore, the study highlighted the minimal occurrence of hypertensive crises associated with STS, suggesting a safe and well-tolerated approach. This research offers promising evidence for the use of STS as a potential treatment option for major depressive disorder, particularly for patients who prefer a convenient and consistent delivery method.

A New Era of Treatment: Transdermal Delivery for Mental Health

The development of STS represents a significant advancement in the treatment of major depressive disorder. This research underscores the potential benefits of transdermal drug delivery, offering a more consistent and predictable therapeutic experience. It also highlights the need for continued research and development of transdermal medications to address a wide range of medical conditions.

Dr. Camel's Conclusion

The selegiline transdermal system is like a steady desert breeze, providing a consistent and effective therapeutic effect for managing major depressive disorder. This research offers promising evidence for the use of STS, highlighting the potential benefits of transdermal drug delivery for mental health.

Date :
  1. Date Completed 2016-06-01
  2. Date Revised 2016-06-17
Further Info :

Pubmed ID

26427518

DOI: Digital Object Identifier

10.1586/17512433.2016.1093416

Related Literature

Article Analysis
・Effects of selegiline transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.